Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.62 |
| ▸ | HPGD | P15428 | 4/20 | 0.62 |
| ▸ | GAA | P10253 | 3/20 | 0.62 |
| ▸ | LMNA | P02545 | 3/20 | 0.62 |
| ▸ | HTT | P42858 | 2/20 | 0.62 |
| ▸ | USP2 | O75604 | 1/20 | 0.62 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | MAPT | P10636 | 2/20 | 0.56 |
| ▸ | GFER | P55789 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.54 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.52 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL518401 | 0.81 | GAA (0.64) | SMN1; SMN2HPGDGAALMNAHTT | |
| SCHEMBL518400 | 0.81 | GAA (0.64) | SMN1; SMN2HPGDGAALMNAHTT | |
| SCHEMBL4230443 | 0.81 | DDX3X (0.65) | SMN1; SMN2HPGDGAALMNAHTT | |
| SCHEMBL10192117 | 0.79 | NPSR1 (0.88) | SMN1; SMN2HPGDGAALMNAHTT | |
| SCHEMBL27923186 | 0.79 | GAA (0.62) | SMN1; SMN2HPGDGAALMNAHTT | |
| SCHEMBL23109077 | 0.79 | MGLL (0.64) | SMN1; SMN2HPGDGAALMNAHTT | |
| SCHEMBL25547538 | 0.79 | GAA (0.62) | SMN1; SMN2HPGDGAALMNAHTT | |
| SCHEMBL12160117 | 0.79 | MAPK1 (0.72) | SMN1; SMN2HPGDGAALMNAHTT | |
| SCHEMBL3926664 | 0.79 | GRK2 (0.64) | SMN1; SMN2HPGDGAALMNAHTT | |
| SCHEMBL375186 | 0.78 | NAMPT (0.67) | SMN1; SMN2HPGDGAALMNAHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9078902-B2 | Triazine derivatives and their therapeutical applications | NANTBIOSCIENCE, INC. (US) | 2015-07-14 | — | — | US | disclosed |
| US-20120196860-A1 | Triazine derivatives and their therapeutical applications | CALIFORNIA CAPITAL EQUITY, LLC (US) | 2012-08-02 | — | — | US | disclosed |
| US-20120172361-A1 | TRIAZINE DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS | CALIFORNIA CAPITAL EQUITY, LLC (US) | 2012-07-05 | — | — | US | disclosed |
| WO-2010144550-A1 | TRIAZINE DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS | ABRAXIS BIOSCIENCE, LLC (US) | 2010-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120172361-A1 | TRIAZINE DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS | CYP3A5, CYP11B2, ABCB1 | SMN1; SMN2 1130/4885HPGD 1190/4885GAA 417/4885 |
| US-20120196860-A1 | Triazine derivatives and their therapeutical applications | MAP3K2, MAP3K5, MAP4K2 | SMN1; SMN2 3260/4885HPGD 2372/4885GAA 2683/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.